Association of Asprosin in Periodontitis and Acute Coronary Syndrome

Ataturk University

Status: Completed

Conditions: Periodontal Diseases; Cardiovascular Diseases

Treatments: Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05647902

MIC3

Details and patient eligibility

About

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.

Full description

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Cardiovascular and periodontal diseases are closely related, presenting a triad association. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activatesinvestigators the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation.

Enrollment: 120 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

For Healthy group

• All individuals were generally healthy,
• non-smoking For Myocard Infarctus group
• patients with ST elevation of Myocardial Infactus
• patient with less than ten teeth

Exclusion criteria

• Smokers or those with diabetes or other inflammatory disease
• Pregnant or breastfeeding women
• None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
• None has a contagious disease such as HIV or AIDS

Trial design

120 participants in 2 patient groups

Healthy Group

Description:

70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.

Treatment:

Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis

Myocard Infactus Group

Description:

50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.

Treatment:

Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis